The GABAA receptor is a ligand-gated chloride channel that, upon binding the neurotransmitter GABA, mediates neuronal inhibition throughout the brain. In addition to binding GABA, the receptor is allosterically modulated by a variety of therapeutic agents, such as benzodiazepines (BZ) and barbiturates, that bind to distinct sites on the receptor. Many GABAA receptor subunits (?1-6, ?1-3, ?1-3, ?, ?, ? and ?) exist and are preferentially assembled into pentameric structures within the endoplasmic reticulum (ER). Once assembled, the receptors are exported to the cell surface to participate in GABAergic neurotransmission. Surprisingly, little is known regarding receptor biogenesis despite the obvious importance of this process for maintaining appropriate levels of cell surface receptors. Using a recombinant expression system, we have recently discovered that the neurotransmitter GABA can act as a ligand chaperone in the ER to promote receptor biogenesis, thus increasing surface expression of GABAA receptors. The proposed studies will further investigate this finding. These experiments will examine 1) if GABA acts as a physiological ligand chaperone of native GABAA receptors in primary neuronal cultures;2) whether the GABA chaperone effect displays receptor subtype selectivity;3) whether AAV-GAD67 transduction can promote GABA chaperoning in neuronal cultures and 4) the mechanism by which the ligand chaperoning occurs. Experiments will be conducted on recombinant GABAA receptors expressed in HEK 293 cells as well as native receptors in primary neuronal cultures. A multifaceted approach involving fluorescence confocal microscopy, flow cytometry and biochemical techniques will be used.

Public Health Relevance

The GABAA receptor is a neurotransmitter receptor associated with both psychiatric disease (anxiety) and neurological disorders (epilepsy and sleep disorders). Therapeutic drugs that target the GABAA receptor, such as benzodiazepines and barbiturates, are widely used to treat these diseases. The proposed research will further our understanding of how these receptors are synthesized in the cell and transported to the cell surface where they participate in neurotransmission.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
2R01MH062640-06A1
Application #
7688408
Study Section
Special Emphasis Panel (ZRG1-MDCN-F (02))
Program Officer
Nadler, Laurie S
Project Start
2000-12-01
Project End
2011-04-30
Budget Start
2009-05-07
Budget End
2010-04-30
Support Year
6
Fiscal Year
2009
Total Cost
$434,869
Indirect Cost
Name
Louisiana State University Hsc Shreveport
Department
Biochemistry
Type
Schools of Medicine
DUNS #
095439774
City
Shreveport
State
LA
Country
United States
Zip Code
71103
Leidenheimer, Nancy J (2017) Cognate Ligand Chaperoning: a Novel Mechanism for the Post-translational Regulation of Neurotransmitter Receptor Biogenesis. Front Cell Neurosci 11:245
Wang, Ping; Eshaq, Randa S; Meshul, Charles K et al. (2015) Neuronal gamma-aminobutyric acid (GABA) type A receptors undergo cognate ligand chaperoning in the endoplasmic reticulum by endogenous GABA. Front Cell Neurosci 9:188
Leidenheimer, Nancy J; Ryder, Katelyn G (2014) Pharmacological chaperoning: a primer on mechanism and pharmacology. Pharmacol Res 83:10-9
Eshaq, Randa S; Stahl, Letha D; Stone 2nd, Randolph et al. (2010) GABA acts as a ligand chaperone in the early secretory pathway to promote cell surface expression of GABAA receptors. Brain Res 1346:1-13
Huang, Renqi; He, Shaoqing; Chen, Zhenglan et al. (2007) Mechanisms of homomeric alpha1 glycine receptor endocytosis. Biochemistry 46:11484-93
Herring, Dina; Huang, RenQi; Singh, Meharvan et al. (2005) PKC modulation of GABAA receptor endocytosis and function is inhibited by mutation of a dileucine motif within the receptor beta 2 subunit. Neuropharmacology 48:181-94